A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

H. L. Kindler, D. A. Richards, L. E. Garbo, E. B. Garon, J. J. Stephenson, C. M. Rocha-Lima, H. Safran, D. Chan, D. M. Kocs, F. Galimi, J. Mcgreivy, S. L. Bray, Y. Hei, E. G. Feigal, E. Loh, C. S. Fuchs

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Background: We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death receptor 5) combined with gemcitabine in a randomized phase 2 trial in patients with metastatic pancreatic cancer. Patients and methods: Patients with a previously untreated metastatic pancreatic adenocarcinoma and an Eastern Cooperative Oncology Group (ECOG) performance status ≤1 were randomized 1 1 1 to i.v. gemcitabine 1000 mg/m. 2 (days 1, 8, and 15 of each 28-day cycle) combined with open-label ganitumab (12 mg/kg every 2 weeks [Q2W]), double-blind conatumumab (10 mg/kg Q2W), or double-blind placebo Q2W. The primary end point was 6-month survival rate. Results: In total, 125 patients were randomized. The 6-month survival rates were 57% (95% CI 41-70) in the ganitumab arm, 59% (42-73) in the conatumumab arm, and 50% (33-64) in the placebo arm. The grade ≥3 adverse events in the ganitumab, conatumumab, and placebo arms, respectively, included neutropenia (18/22/13%), thrombocytopenia (15/17/8%), fatigue (13/12/5%), alanine aminotransferase increase (15/5/8%), and hyperglycemia (18/2/3%). Conclusions: Ganitumab combined with gemcitabine had tolerable toxicity and showed trends toward an improved 6-month survival rate and overall survival. Additional investigation into this combination is warranted. Conatumumab combined with gemcitabine showed some evidence of activity as assessed by the 6-month survival rate.

Original languageEnglish
Article numbermds142
Pages (from-to)2834-2842
Number of pages9
JournalAnnals of Oncology
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

gemcitabine
Pancreatic Neoplasms
Placebos
Survival Rate
TNF-Related Apoptosis-Inducing Ligand Receptors
Somatomedin Receptors
Neutropenia
Alanine Transaminase
Hyperglycemia
Thrombocytopenia
Fatigue
Adenocarcinoma
conatumumab
AMG 479
Safety
Survival

Keywords

  • AMG 479
  • Conatumumab
  • Ganitumab
  • Gemcitabine
  • Pancreatic cancer
  • Phase 2 trial

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Kindler, H. L., Richards, D. A., Garbo, L. E., Garon, E. B., Stephenson, J. J., Rocha-Lima, C. M., ... Fuchs, C. S. (2012). A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology, 23(11), 2834-2842. [mds142]. https://doi.org/10.1093/annonc/mds142

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. / Kindler, H. L.; Richards, D. A.; Garbo, L. E.; Garon, E. B.; Stephenson, J. J.; Rocha-Lima, C. M.; Safran, H.; Chan, D.; Kocs, D. M.; Galimi, F.; Mcgreivy, J.; Bray, S. L.; Hei, Y.; Feigal, E. G.; Loh, E.; Fuchs, C. S.

In: Annals of Oncology, Vol. 23, No. 11, mds142, 01.11.2012, p. 2834-2842.

Research output: Contribution to journalArticle

Kindler, HL, Richards, DA, Garbo, LE, Garon, EB, Stephenson, JJ, Rocha-Lima, CM, Safran, H, Chan, D, Kocs, DM, Galimi, F, Mcgreivy, J, Bray, SL, Hei, Y, Feigal, EG, Loh, E & Fuchs, CS 2012, 'A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer', Annals of Oncology, vol. 23, no. 11, mds142, pp. 2834-2842. https://doi.org/10.1093/annonc/mds142
Kindler, H. L. ; Richards, D. A. ; Garbo, L. E. ; Garon, E. B. ; Stephenson, J. J. ; Rocha-Lima, C. M. ; Safran, H. ; Chan, D. ; Kocs, D. M. ; Galimi, F. ; Mcgreivy, J. ; Bray, S. L. ; Hei, Y. ; Feigal, E. G. ; Loh, E. ; Fuchs, C. S. / A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. In: Annals of Oncology. 2012 ; Vol. 23, No. 11. pp. 2834-2842.
@article{e0e7614fb75f4512bc200c4a8c7ce9d7,
title = "A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer",
abstract = "Background: We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death receptor 5) combined with gemcitabine in a randomized phase 2 trial in patients with metastatic pancreatic cancer. Patients and methods: Patients with a previously untreated metastatic pancreatic adenocarcinoma and an Eastern Cooperative Oncology Group (ECOG) performance status ≤1 were randomized 1 1 1 to i.v. gemcitabine 1000 mg/m. 2 (days 1, 8, and 15 of each 28-day cycle) combined with open-label ganitumab (12 mg/kg every 2 weeks [Q2W]), double-blind conatumumab (10 mg/kg Q2W), or double-blind placebo Q2W. The primary end point was 6-month survival rate. Results: In total, 125 patients were randomized. The 6-month survival rates were 57{\%} (95{\%} CI 41-70) in the ganitumab arm, 59{\%} (42-73) in the conatumumab arm, and 50{\%} (33-64) in the placebo arm. The grade ≥3 adverse events in the ganitumab, conatumumab, and placebo arms, respectively, included neutropenia (18/22/13{\%}), thrombocytopenia (15/17/8{\%}), fatigue (13/12/5{\%}), alanine aminotransferase increase (15/5/8{\%}), and hyperglycemia (18/2/3{\%}). Conclusions: Ganitumab combined with gemcitabine had tolerable toxicity and showed trends toward an improved 6-month survival rate and overall survival. Additional investigation into this combination is warranted. Conatumumab combined with gemcitabine showed some evidence of activity as assessed by the 6-month survival rate.",
keywords = "AMG 479, Conatumumab, Ganitumab, Gemcitabine, Pancreatic cancer, Phase 2 trial",
author = "Kindler, {H. L.} and Richards, {D. A.} and Garbo, {L. E.} and Garon, {E. B.} and Stephenson, {J. J.} and Rocha-Lima, {C. M.} and H. Safran and D. Chan and Kocs, {D. M.} and F. Galimi and J. Mcgreivy and Bray, {S. L.} and Y. Hei and Feigal, {E. G.} and E. Loh and Fuchs, {C. S.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1093/annonc/mds142",
language = "English",
volume = "23",
pages = "2834--2842",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

AU - Kindler, H. L.

AU - Richards, D. A.

AU - Garbo, L. E.

AU - Garon, E. B.

AU - Stephenson, J. J.

AU - Rocha-Lima, C. M.

AU - Safran, H.

AU - Chan, D.

AU - Kocs, D. M.

AU - Galimi, F.

AU - Mcgreivy, J.

AU - Bray, S. L.

AU - Hei, Y.

AU - Feigal, E. G.

AU - Loh, E.

AU - Fuchs, C. S.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Background: We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death receptor 5) combined with gemcitabine in a randomized phase 2 trial in patients with metastatic pancreatic cancer. Patients and methods: Patients with a previously untreated metastatic pancreatic adenocarcinoma and an Eastern Cooperative Oncology Group (ECOG) performance status ≤1 were randomized 1 1 1 to i.v. gemcitabine 1000 mg/m. 2 (days 1, 8, and 15 of each 28-day cycle) combined with open-label ganitumab (12 mg/kg every 2 weeks [Q2W]), double-blind conatumumab (10 mg/kg Q2W), or double-blind placebo Q2W. The primary end point was 6-month survival rate. Results: In total, 125 patients were randomized. The 6-month survival rates were 57% (95% CI 41-70) in the ganitumab arm, 59% (42-73) in the conatumumab arm, and 50% (33-64) in the placebo arm. The grade ≥3 adverse events in the ganitumab, conatumumab, and placebo arms, respectively, included neutropenia (18/22/13%), thrombocytopenia (15/17/8%), fatigue (13/12/5%), alanine aminotransferase increase (15/5/8%), and hyperglycemia (18/2/3%). Conclusions: Ganitumab combined with gemcitabine had tolerable toxicity and showed trends toward an improved 6-month survival rate and overall survival. Additional investigation into this combination is warranted. Conatumumab combined with gemcitabine showed some evidence of activity as assessed by the 6-month survival rate.

AB - Background: We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death receptor 5) combined with gemcitabine in a randomized phase 2 trial in patients with metastatic pancreatic cancer. Patients and methods: Patients with a previously untreated metastatic pancreatic adenocarcinoma and an Eastern Cooperative Oncology Group (ECOG) performance status ≤1 were randomized 1 1 1 to i.v. gemcitabine 1000 mg/m. 2 (days 1, 8, and 15 of each 28-day cycle) combined with open-label ganitumab (12 mg/kg every 2 weeks [Q2W]), double-blind conatumumab (10 mg/kg Q2W), or double-blind placebo Q2W. The primary end point was 6-month survival rate. Results: In total, 125 patients were randomized. The 6-month survival rates were 57% (95% CI 41-70) in the ganitumab arm, 59% (42-73) in the conatumumab arm, and 50% (33-64) in the placebo arm. The grade ≥3 adverse events in the ganitumab, conatumumab, and placebo arms, respectively, included neutropenia (18/22/13%), thrombocytopenia (15/17/8%), fatigue (13/12/5%), alanine aminotransferase increase (15/5/8%), and hyperglycemia (18/2/3%). Conclusions: Ganitumab combined with gemcitabine had tolerable toxicity and showed trends toward an improved 6-month survival rate and overall survival. Additional investigation into this combination is warranted. Conatumumab combined with gemcitabine showed some evidence of activity as assessed by the 6-month survival rate.

KW - AMG 479

KW - Conatumumab

KW - Ganitumab

KW - Gemcitabine

KW - Pancreatic cancer

KW - Phase 2 trial

UR - http://www.scopus.com/inward/record.url?scp=84862531853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862531853&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds142

DO - 10.1093/annonc/mds142

M3 - Article

VL - 23

SP - 2834

EP - 2842

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

M1 - mds142

ER -